Azim Premji-Linked Fund Exits Medplus Health Services For Rs 482 Crore; Kotak MF, Invesco Among Buyers
An affiliate of billionaire Azim Premji-backed Premji Invest Ltd. divested its entire stake in Medplus Health Services Ltd. for Rs 482 crore through block deal on Monday.
The selling entity, Pi Opportunities Fund - I, offloaded a total of 68.93 lakh shares, that represents 5.76% equity of Medplus Health Services, at Rs 700 apiece.
The fund is owned and controlled by Premji Invest, the private equity and venture capital investment arm of the Premji Foundation. The Premji Foundation was set up to advance the philanthropic initiatives of Premji Invest and is ultimately controlled by the Wipro Ltd founder.
According to the block deal data available on the National Stock Exchange, SBI Mutual Fund also sold 10 lakh shares or 0.83% stake in Medplus Health Services for Rs 70 crore.
On the other hand, Kotak Mahindra Mutual Fund purchased 30.71 lakh shares (2.56%) at Rs 700 per share, as did Invesco Mutual Fund, which also acquired 30.71 lakh shares (2.56%) at the same price.
Additionally, Franklin Templeton Mutual Fund bought 16.07 lakh shares (1.34%), while Morgan Stanley Asia Singapore acquired 1.42 lakh shares (0.11%) at the same price.
In August, Lavender Rose Investment exited Medplus Health Services after offloading 1.35 shares, representing an 11.35% stake in the Hyderabad-based pharmacy retailer for Rs 836 crore.
ICICI Prudential India Opportunities Fund had acquired 18.12 lakh shares for an aggregate amount of Rs 111.6 crore, ICICI Prudential Pharma Healthcare & Diagnostics bought a 1.43% stake at Rs 616 per share, and the Government of Singapore bought 11.54 lakh shares at Rs 616.2 apiece.
Medplus Health Services provides a diverse range of products, including pharmaceuticals, wellness items, medicines, vitamins, medical devices, test kits, and FMCG products such as home and personal care essentials, toiletries, baby care products, soaps, detergents, and sanitisers.
Shares of Medplus Health Services closed 2.1% higher at Rs 719 per share on the NSE, compared to a 0.34% decline in the benchmark Nifty 50. The share price has fallen 14% in the last 12 months and 4% on a year-to-date basis.
All six analysts tracking Medplus Health Services have a 'buy' rating on the stock, with a target price of Rs 927, implying a return potential of 29%, as per Bloomberg data.
-
We May Need Another Tukaram Mundhe To Fight Air Pollution | The Reason Why
Developers may install basic measures such as sprinklers and green nets, resume work, and continue violating rules when this equipment stops working.
-
Extracting Value From Battery Scrap Could Be Challenging For India | The Reason Why
A discarded lithium-ion battery still contains valuable materials such as lithium, nickel and cobalt. These can be recovered and reused. When such batteries are crushed and shredded, they produce a dark powder called black mass.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.